Clinical trial
Biomarkers for Rapid Identification of Treatment Effectiveness in Major Depression (BRITE-MD), a Prospective, Randomized, Multi-center Study to Determine the Efficacy of Selected EEG and Genotype Biomarkers for Predicting Response to Antidepressant Therapy With Escitalopram, Bupropion XL, or a Combination Treatment Regimen.
NCT00289523 is registered in ClinicalTrials.gov with Medtronic - MITG as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Biomarkers for Rapid Identification of Treatment Effectiveness in Major Depression (BRITE-MD), a Prospective, Randomized, Multi-center Study to Determine the Efficacy of Selected EEG and Genotype Biomarkers for Predicting Response to Antidepressant Therapy With Escitalopram, Bupropion XL, or a Combination Treatment Regimen.
- Lead sponsor
- Medtronic - MITG
- Phase
- Observational
- Overall status
- Completed
- Start date
- January 31, 2006
- Completion date
- July 31, 2007
- Enrollment
- 375 (actual)
- Sites
- 10
Conditions
As the registry lists them; a condition with its own page is linked.